Clinical & Pharma

Is Nepal Prepared for a Nipah Virus Outbreak?
Clinical & Pharma Is Nepal Prepared for a Nipah Virus Outbreak?

The emergence of a deadly Nipah virus outbreak in neighboring India has cast a long shadow across the border, compelling Nepal's Ministry of Health and Population to issue a sweeping public health advisory. While the World Health Organization (WHO) currently assesses the public health risk to the

What Is the Backbone of Medical Research?
Clinical & Pharma What Is the Backbone of Medical Research?

Every groundbreaking medical treatment and public health policy that shapes modern life rests upon a complex and often invisible framework of mathematical precision and analytical rigor. Behind the celebrated discoveries of new drugs and the development of life-saving vaccines lies a discipline

Is This Namibia's Path to Universal Healthcare?
Clinical & Pharma Is This Namibia's Path to Universal Healthcare?

The Namibian government is moving forward with a transformative healthcare reform, presenting a Universal Health Coverage (UHC) bill that aims to bridge the significant gap between the nation's public and private health sectors. The Ministry of Health and Social Services has initiated a crucial

Is Policy Ignoring the Long-Term Risks of COVID?
Clinical & Pharma Is Policy Ignoring the Long-Term Risks of COVID?

While the acute phase of the global health crisis has subsided from public consciousness, a far more insidious threat continues to unfold with profound implications for millions worldwide. Years after the initial outbreak, society has largely moved on, adopting a narrative of endemic coexistence

Canadian Trial Tests Novel Cream to Reduce Burn Scars
Clinical & Pharma Canadian Trial Tests Novel Cream to Reduce Burn Scars

For individuals who have survived severe burn injuries, the initial trauma is often just the beginning of a long and arduous journey, with the subsequent scarring presenting a formidable, lifelong challenge. These scars can do more than alter one's appearance; they frequently cause chronic pain and

Why Is AstraZeneca Betting $15 Billion on China?
Clinical & Pharma Why Is AstraZeneca Betting $15 Billion on China?

In a move that reverberates across the global pharmaceutical landscape, AstraZeneca has committed to a monumental $15 billion long-term investment in China, signaling a profound strategic alignment with the nation's rapidly ascending role as a biopharmaceutical powerhouse. This massive financial

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later